secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001847367-25-000048
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis Q3 net loss $110.8M; cash $377.7M; Phase 3 psoriasis data expected Q1 2026
--------------------------------------------------------------------------------

- Net loss of $110.8M for Q3 2025 vs. $93.1M in Q3 2024; R&D expenses rose to $97.8M from $87.8M.
- Cash, cash equivalents and marketable securities totaled $377.7M as of September 30, 2025.
- Topline Phase 3 ONWARD data for envudeucitinib in plaque psoriasis expected early Q1 2026; Phase 2b SLE data in Q3 2026.
- Collaboration revenue of $2.1M from Kaken Pharmaceutical in Q3 2025.
- Company expects existing cash to fund pipeline and operations into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/0001847367-25-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001847367-25-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer